PMC16 PROPOSED CHANGES TO PHYSICIAN FEE SCHEDULE: 2007 PRACTICE EXPENSE CONCEPTUAL METHODOLOGY  by Pierce, CA & Baker, JJ
A274 Abstracts
PMC13
EMPIRICAL RESEARCH FOR WILLINGNESSTO PAYFOR ONE
QALY GAIN
Ohkusa Y, Sugawara T
National Institute of Infectious Diseases, Shinjuku,Tokyo, Japan
OBJECTIVE: The monetary evaluation for QALY gain is neces-
sary and important information for decision making about
medical or public health policies. Even though there is one empir-
ical research about it, it used direct methods to estimate its WTP
and thus it has a lot of problems. This paper aims to study the
same purpose but by using Conjoint analysis. METHODS: A
survey was conducted in the 2005 ﬁscal year and questionnaires
were distributed and collected from 773 households, of which
the return rate was 88%. The subjects are 1297 adults over age
20. In addition to socio-economic characteristics, in this survey
respondents were asked a hypothetical question for Conjoint
analysis; whether they would agree to the medical care under the
hypothetical situation in regards to cost, duration, the number
of patients, and health status. We also performed sensitive analy-
sis in regards to explanatory variables in the estimation equa-
tion, discount factors, and QOL evaluation for health status.
RESULTS: In all equation, the estimated coefﬁcients of total cost
are signiﬁcantly negative and those of QALY gain are signiﬁ-
cantly positive. CONCLUSIONS: WTP per QALY gain is esti-
mated to be 635 to 675 thousand Japanese yen or 5773 to 6136
US$ assuming 1US$ = 110 Japanese yen. Income does not affect
WTP per QALY signiﬁcantly.
PMC14
MEASURING PATIENT-REPORTED SIDE EFFECTS OF DRUGS:
ITS IMPORTANCE AND METHODOLOGICAL CHALLENGES
Foster JM1,Van der Molen T1, Caeser M2, Hannaford P3
1University of Groningen, Groningen,The Netherlands, 2ALTANA
Pharma AG, Konstanz, Germany, 3University of Aberdeen, Aberdeen,
Scotland, UK
INTRODUCTION: Side effects include drug-induced symptoms
which are predominantly communicated by patient self-report.
This year, the FDA produced draft recommendations for the val-
idation of patient-reported outcomes, for use in medical product
development studies. The growing interest in side effects in
medical research and the regulatory environment, presents an
urgent need for properly developed patient-reported outcome
measures of drug side effects. These measures must be valid, reli-
able and reproducible. METHODS: To assess the psychometric
properties of patient-reported side effect symptom scales, and to
describe and evaluate the methodologies used to create them.
RESULTS: Fifteen existing scales were identiﬁed and reviewed.
There was wide variation in the extent to which the psychome-
tric properties of the instruments had been reported or tested.
There were disagreements amongst scale developers concerning
the appropriateness of use of certain reliability tests which are
usually routinely undertaken during questionnaire development.
The responsiveness testing of side effect scales may be problem-
atic to carry out and testing was limited amongst reviewed scales.
Since any symptom of a drug intervention may be associated
with everyday health problems, the disease being treated, the
drug treatment or a combination of these causes, measuring
drug-related side effects is complicated. This complexity impacts
upon all aspects of the psychometric testing of patient–reported
scales, creating unique challenges for their developers, who must
create tools which appropriately discriminate between side
effects and symptoms. CONCLUSION: The potential usefulness
of patient-reported side effect scales is broad: from research
outcome to clinical monitoring. However, a consensus must be
reached on suitable methods for the development of such scales.
The complexity of side effect measurement may necessitate the
introduction of new approaches for the assessment of the relia-
bility and responsiveness of these scales.
PMC15
HOSPITAL PHARMACY DRUG DELIVERY TIME: A WORK FLOW
MANAGEMENT ISSUE
Pierce CA1, Baker JJ2, McClard C2
1The Resource Group, Richﬁeld, OH, USA, 2The Resource Group,
Pickton,TX, USA
OBJECTIVE: Drug delivery delays are a recurring management
issue that causes costly disruptions in hospital work ﬂow. This
project examines reported delivery time from the hospital phar-
macy to the hospital outpatient department where the drug or
biologic is to be administered. The focus is upon drugs that are
expensive, that require reconstitution and that are often prepared
only after notiﬁcation that the patient has arrived. METHODS:
Data were collected from 54 hospital pharmacies, including on-
site observations of pharmacy activities and related infusion
therapy in hospital outpatient departments (HOPDs) in 19 states
(n = 24) and from a telephone survey of other hospital DOPs
located in 17 states (n = 30). Survey instruments were pretested.
The sampling frame was a broad-based convenience sample.
Facility-speciﬁc data were entered into a database and matched
with facility demographics retrieved from a government data-
base. Unit of analysis was the pharmacy. Statistical analysis
yielded descriptive statistics. RESULTS: The on-site observers
determined that those HOPDs that delivered the drug to be
infused from the main pharmacy (54.2%) incurred a statistically
signiﬁcant mean wait time of 37.5 minutes. The remaining facil-
ities (45.8%) incurred negligible wait times because the drug was
reconstituted adjacent to or on site. Respondents to the tele-
phone survey reported a 17.4 minute mean delivery time regard-
less of pharmacy location. Tasks contributing to wait time
included mixing, dispensing and transporting. Delivery was
made by pharmacy technicians in 80.8% of facilities and by spe-
cially designated transport staff provided by the pharmacy
department in 19.2% of the facilities surveyed. CONCLU-
SIONS: Hospital pharmacy decision-makers need actionable
information in order to better manage drug delivery delays that
disrupt work ﬂow and decrease patient satisfaction. This study
provides detailed activity analysis information and process
mapping that can be readily applied to facility-speciﬁc relevant
pharmacy stafﬁng and management decisions.
PMC16
PROPOSED CHANGES TO PHYSICIAN FEE SCHEDULE: 2007
PRACTICE EXPENSE CONCEPTUAL METHODOLOGY
Pierce CA1, Baker JJ2
1The Resource Group, Richﬁeld, OH, USA, 2The Resource Group,
Pickton,TX, USA
OBJECTIVE: The Centers for Medicare and Medicaid Services
(CMS) has proposed methodological changes to the computation
of 2007 physician fee schedule practice expense. The proposed
changes appear to reduce payment for drug administration. This
study explores the methodological design of these proposed
changes and seeks to identify primary drivers within the method-
ology. METHODS: Various methods of computing practice
expense for 2007 as proposed by CMS were collected and cate-
gorized in a methods database format. Data sources and formu-
las for each proposed method were identiﬁed. Current
computation methods in effect for calendar year 2006 were then
identiﬁed and divided into segments for purposes of comparison.
Proposed methods were compared against each other and against
the payment structure currently in effect. This comparative
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analysis highlighted methodological drivers. RESULTS: CMS ini-
tially proposed four methods of computing practice expense in
2007. Three potential data sources were identiﬁed: the Socioe-
conomic Monitoring System (SMS); the Medicare Economic
Index (MEI); and the Clinical Practice Expert Panel (CPEP). The
four proposed methods utilized various combinations of these
sources. Each proposed formula was based upon a series of allo-
cations that resulted in different percentages assigned to differ-
ent subcomponents of the relevant methodology. Comparative
analysis revealed signiﬁcant differentials. Payments for drug
administration in the physician’s ofﬁce would be reduced by all
four proposed methods. Two primary methodological drivers
were identiﬁed: allocation between direct expense and indirect
expense within each formula and the volume-based allocation
method, whereby specialty impacts are recognized but are then
weighted by specialty-speciﬁc volume. CONCLUSIONS: Many
physician fee schedule payment rates in 2007, including drug
administration procedures, may be signiﬁcantly impacted by pro-
posed changes to the practice expense computation methods. It
is vital for service provider decision-makers to monitor and
understand relevant CMS proposals. Otherwise, if signiﬁcant
underpayment occurs in 2007, patient access may be negatively
affected.
PMC17
MONITORING OF PHARMACEUTICAL COST OF REIMBURSED
MEDICINES BY COMBINING OFFICIAL PHARMACY INVOICE
DATA WITH COMMERCIAL IMS SALES DATA
Van Wilder P,Arickx F,Van Haeren E, Bormans V
RIZIV-INAMI, Brussels, Belgium
OBJECTIVES: In Belgium reimbursement submissions must
contain scientiﬁc and ﬁnancial elements. The ﬁnancial part relies
on budget impact (BI) estimates from the payer’s perspective for
the next 3 years. Real cost monitoring is difﬁcult because ofﬁcial
cost data become available with a substantial delay while com-
mercial IMS data measure total sales. Our aim was to develop a
method to monitor pharmaceutical expenses in Belgium and
compare the outcome with the expected costs of the BI- estima-
tion: a method combining both data sources allowed to monitor
in a timely manner only the reimbursed pharmaceutical cost.
METHODS: The method was applied on the class of cholesterol
lowering drugs representing 9% of ambulatory expenses. BI-esti-
mations were provided in the applicant’s dossier. Monthly IMS-
sales data (=S, IMS-Health) and ofﬁcial cost data (=C, Riziv) were
extracted from the respective databases. RESULTS: All correla-
tions between historical monthly product data from both sources
yielded an R2 > 0.75 which was considered as a cut-off to apply
the method (minimal R2 = 0.8164). Expected reimbursement
pharmaceutical cost was calculated as: Expected C = S/k where
k is the average monthly ratio of S to C during a common 12
month period. The expected C calculation extends real C data by
6 months. Quality control of the method was assessed by com-
paring the expected C and real C yielding a mean monthly error
lower than 5% with a 3 month cumulated error of less than 2%.
BI-estimates were inferior to expected and real C. CONCLU-
SIONS: A method was developed to predict 3rd payer’s pharma-
ceutical cost combining recent commercial sales data and ofﬁcial
but less recent cost data ensuring reliable application of this
method for control of estimates of BI.
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USING DISTANCE LEARNING TO UNDERSTAND DISCRETE
EVENT SIMULATION
Hunting B, Moller J, Caro JJ
Caro Research Institute, Concord, MA, USA
OBJECTIVES: The many beneﬁts of pharmacoeconomic model-
ing using Discrete Event Simulation (DES) have increased inter-
est in this methodology. A paucity of courses applied to medical
problems however, combined with busy schedules prohibit many
professionals from familiarizing themselves with the technique.
Meeting these needs requires training that can be conducted over
the internet. METHODS: A distance learning course was devel-
oped to provide a basic understanding of DES. Using Flash tech-
nology, an internationally accepted web standard, learning
materials were organized into discrete Lessons of online infor-
mation. Each Lesson is a collection of video, narration, and text
explaining a particular aspect of DES such as its theoretical
underpinnings, examples of implemented DES solutions, and in-
depth explanations of model logic. While Lessons are grouped
together in Modules which address a speciﬁc range of concepts,
each Lesson can also stand on its own. This allows the student
to approach the course at their own pace and navigate the cur-
riculum according to personal interest and experience level. This
granular organizational method also enables individual lessons
to serve as reference materials. RESULTS: The interactive course
allows students to manipulate ﬂowchart exercises, self-certify
their knowledge through instantly processed quizzes, and contact
course administrators with questions. Accessing the course
requires only a broadband internet connection, a standard web
browser and the Flash player plug-in. CONCLUSIONS: When
considering the time and expense of attending geographically dis-
persed educational seminars, as well as the difﬁculties associated
with participating in large group lectures, the advantages of a
tailored, interactive online course become clear. Combining an
interactive multimedia presentation approach with a deep cur-
riculum and an at-your-own-pace learning process, the online
DES course provides students with an effective and convenient
solution for learning about DES in the pharmacoeconomic ﬁeld.
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THE EPIDEMIOLOGIC, HEALTH-RELATED QUALITY OF LIFE,
AND ECONOMIC BURDEN OF GASTROINTESTINAL
STROMAL TUMORS
Reddy P1, Boci K2, Charbonneau C3, Pashos CL1
1Abt Associates Inc, Lexington, MA, USA, 2Abt Associates Inc,
Bethesda, MD, USA, 3Pﬁzer, New York, NY, USA
OBJECTIVES: Gastrointestinal stromal tumors (GIST) is the rel-
atively new term for gastric and intestinal smooth muscle tumors
arising from mesenchymal or connective tissue. Knowledge of
the epidemiologic, health-related quality of life (HRQL), and
economic burden of GIST is important from payer, provider, 
and patient perspectives and may help guide coverage and treat-
ment decisions for treatments recently available. METHODS:
PubMed and six scientiﬁc meeting databases were searched for
studies of GIST and epidemiology, HRQL, or economics. Rele-
vant publications were assessed as to whether they provided orig-
inal empirical research. RESULTS: Eleven publications met the
review criteria: eight provided data on GIST incidence, and one
each on prevalence, HRQL, and cost. Incident cases were iden-
tiﬁed by medical record review or through extant databases with
prospective conﬁrmation by immunohistochemical staining in
six studies. The annualized incidence of GIST (cases per million)
was: United States (U.S.) (6.8), Iceland (11.0), The Netherlands
(12.7), Italy (13), Taiwan (13.7) Sweden (14.5), Finland (10–20),
and France (20.4). Prevalence was estimated at 129 cases per
million in Sweden. On the Functional Illness of Chronic
Therapy-fatigue instrument, GIST patients scored 40.0 com-
pared to 23.9, 37.6, and 43.6 in anemic cancer, non-anemic
